好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ineligible by 1,000 Cuts: Identifying Epilepsy Clinical Trial Ineligibility from Structured Electronic Health Records
Epilepsy/Clinical Neurophysiology (EEG)
P4 - Poster Session 4 (8:00 AM-9:00 AM)
11-011

We evaluated how structured information in the electronic health records identified the most common co-occurring conditions and vital sign reasons for epilepsy clinical trial ineligibility.

Clinical trials are necessary to evaluate the efficacy and safety of novel epilepsy treatments. New treatments are necessary for the estimated 30% of patients with continued seizures. However, recruitment per site has lessened, requiring more trial sites and increasing costs.

Adults with epilepsy seen in an outpatient encounter by an epileptologist within a 1-year period from 2024 to 2025 were identified from the University of Pittsburgh Medical Center’s electronic health record (EHR) using any International Classification of Diseases, 10th Revision (ICD-10) code for epilepsy (G40.*) or two codes for convulsions (R56.*) separated by 30 days. Based on criteria for currently recruiting trials, excluded co-occurring conditions were identified using ICD-10 codes. Vital signs and demographic information were extracted from the EHR.

We identified 13,678 patients aged between 17.5 and 74.5 years without developmental and epileptic encephalopathy (DEE) codes. Epileptologists saw 26% (3,510) of patients. Of patients who saw epileptologists, eligibility was most limited by co-occurring mental health disorders (excluded 81%), metabolic illness (excluded 57%), and neoplasia (excluded 42%). Body mass index excluded 22% (18% above 35). Only 7% (230) of patients had no exclusions and 14% (497) had one exclusion.

Only 7% of patients seen by epileptologists appeared eligible for clinical trials after evaluating vital signs and co-occurring conditions. Limiting recruitment to epileptologists markedly reduced the number and representativeness of potentially eligible patients. However, reliance on ICD-10 coding not only may have false positives, but also unnecessarily exclude patients with mild co-occurring disease. Integration and analysis of non-structured patient data (e.g., clinical notes) will be necessary for successful application of inclusion and exclusion criteria to achieve the ultimate goal of increased enrollment.

Authors/Disclosures
Wesley Kerr, MD, PhD (University of Pittsburgh)
PRESENTER
Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for QurAlis. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from 好色先生. The institution of Dr. Kerr has received research support from SK Life Science. The institution of Dr. Kerr has received research support from Biohaven Pharmaceuticals. Dr. Kerr has received publishing royalties from a publication relating to health care.
Katherine McFarlane, MS (University of Pittsburgh) Ms. McFarlane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Ms. McFarlane has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace.
Dane E. Prince, MS Mr. Prince has nothing to disclose.
Vijayalakshmi Rajasekaran, MD, FAAN (University of Pittsburgh) The institution of Dr. Rajasekaran has received research support from UCB Pharmaceutical drug trail . The institution of Dr. Rajasekaran has received research support from Xenon and Biohaven. Dr. Rajasekaran has received personal compensation in the range of $0-$499 for serving as a Consultant with NaoX.
James F. Castellano, MD, PhD (UPMC Neurology) Dr. Castellano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuro One medical technologies. The institution of Dr. Castellano has received research support from NIH. The institution of Dr. Castellano has received research support from University of Pittsburgh.
Laura A. Kirkpatrick, MD (UPMC Children's Hospital of Pittsburgh) The institution of Dr. Kirkpatrick has received research support from American Epilepsy Society. The institution of Dr. Kirkpatrick has received research support from Child Neurologist Career Development Program. The institution of Dr. Kirkpatrick has received research support from Child Neurology Foundation. The institution of Dr. Kirkpatrick has received research support from Rosenau Family Research Foundation. The institution of Dr. Kirkpatrick has received research support from Society of Family Planning. The institution of Dr. Kirkpatrick has received research support from Pediatric Epilepsy Research Consortium. Dr. Kirkpatrick has received personal compensation in the range of $500-$4,999 for serving as a Meeting Attendee with One8 Foundation. Dr. Kirkpatrick has received personal compensation in the range of $500-$4,999 for serving as a Meeting Attendee with Brigham and Women's Hospital. Dr. Kirkpatrick has received personal compensation in the range of $0-$499 for serving as a Meeting Attendee with Pediatric Epilepsy Research Consortium. Dr. Kirkpatrick has received personal compensation in the range of $0-$499 for serving as a Grant reviewer with Society of Family Planning. Dr. Kirkpatrick has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Norton Children's Hospital. Dr. Kirkpatrick has a non-compensated relationship as a Board of Directors member with My Epilepsy Story that is relevant to AAN interests or activities.